Direct Visualization ERAT Versus Laparoscopic Appendectomy in Adults With Acute Uncomplicated Appendicitis

NCT ID: NCT07230379

Last Updated: 2025-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

376 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-30

Study Completion Date

2027-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares two ways of treating acute uncomplicated appendicitis, which is a mild form of appendicitis. In the Direct Visualization ERAT group, participants will receive Endoscopic Retrograde Appendicitis Therapy (ERAT). This is a minimally invasive, non-surgical treatment that uses a flexible endoscope passed through the colon to reach the appendix, clear the blockage, and drain the infection. In the Surgery group, participants will undergo Laparoscopic Appendectomy (LA), which is the current standard surgical treatment to remove the appendix. The purpose of this study is to determine whether ERAT is as safe and effective as standard surgery for treating uncomplicated appendicitis.

Before treatment, each participant will have a CT scan of the lower abdomen with contrast to confirm uncomplicated appendicitis and to rule out any signs of more serious infection. Participants will then be randomly assigned to either the ERAT group or the surgery group, and they will be informed of which treatment they will receive. Regardless of the group, all participants will receive the same supportive care, including pain relief, close monitoring, and a single dose of antibiotics before treatment. After the procedure, participants will stay in the hospital for at least 24 hours for observation. Follow-up will include an outpatient visit at 2 weeks, and telephone follow-ups at 1 month, 3 months, 6 months, and 1 year to monitor recovery and ensure that appendicitis does not recur.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, open-label, randomized, non-inferiority trial comparing Direct Visualization Endoscopic Retrograde Appendicitis Therapy (ERAT) with Laparoscopic Appendectomy (LA) for the treatment of adult acute uncomplicated appendicitis (AUA). A total of 376 participants will be enrolled across 14 hospitals in China, and randomized in a 1:1 ratio to either ERAT or LA after providing informed consent.

Adults aged 18 years or older with CT-confirmed first-episode AUA are eligible. Key exclusions include complicated appendicitis, bowel obstruction, intolerance to colonoscopy or bowel preparation, poor operative candidacy, pregnancy, severe organ dysfunction, or concurrent participation in another clinical trial.

Interventions will be performed within 24 hours of admission. ERAT involves the use of a direct visualization appendicoscope to access the appendiceal lumen, irrigate pus and debris, and remove or fragment appendicoliths under direct vision. A short plastic stent may be placed if drainage is required. LA will be performed according to standard laparoscopic surgical techniques. Follow-up assessments will include an outpatient visit at 2 weeks and telephone follow-ups at 1, 3, 6, and 12 months.

The primary outcome is 30-day treatment success, defined as successful completion of the assigned procedure, resolution of symptoms, discharge without further surgery, and absence of recurrence. This study aims to provide robust evidence supporting the safety and effectiveness of ERAT and to inform future clinical guidelines for the management of acute uncomplicated appendicitis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Uncomplicated Appendicitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Direct Visualization ERAT

Undergo direct visualization endoscopic retrograde appendicitis therapy

Group Type EXPERIMENTAL

Direct Visualization Endoscopic Retrograde Appendicitis Therapy

Intervention Type PROCEDURE

Direct visualization ERAT will be performed by experienced endoscopists (≥ 30 prior ERAT cases) under conscious sedation or general anesthesia as needed. A colonoscope with a transparent cap will be advanced to the cecum to expose the appendiceal orifice, and a direct visualization appendicoscope will be introduced through the working channel. The appendiceal lumen will be inspected and irrigated with saline to clear pus and debris, with negative pressure applied for aspiration. Small appendicoliths will be flushed out, while larger ones will be removed using a retrieval basket, stone extractor, or laser lithotripsy. When narrowing or heavy purulence is present, a stent will be inserted for drainage. After confirming adequate drainage, the scope will be withdrawn. If ERAT fails, conversion to laparoscopic or open appendectomy will be performed.

Laparoscopic Appendectomy

Undergo laparoscopic appendectomy

Group Type ACTIVE_COMPARATOR

Laparoscopic appendectomy

Intervention Type PROCEDURE

Laparoscopic appendectomy will be performed under general anesthesia by surgeons with experience in \> 20 procedures, according to standard clinical practice. The resected appendix will be examined for gross features and sent for histopathological confirmation of acute uncomplicated appendicitis. If laparoscopic appendectomy is unsuccessful, conversion to open appendectomy will be performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Direct Visualization Endoscopic Retrograde Appendicitis Therapy

Direct visualization ERAT will be performed by experienced endoscopists (≥ 30 prior ERAT cases) under conscious sedation or general anesthesia as needed. A colonoscope with a transparent cap will be advanced to the cecum to expose the appendiceal orifice, and a direct visualization appendicoscope will be introduced through the working channel. The appendiceal lumen will be inspected and irrigated with saline to clear pus and debris, with negative pressure applied for aspiration. Small appendicoliths will be flushed out, while larger ones will be removed using a retrieval basket, stone extractor, or laser lithotripsy. When narrowing or heavy purulence is present, a stent will be inserted for drainage. After confirming adequate drainage, the scope will be withdrawn. If ERAT fails, conversion to laparoscopic or open appendectomy will be performed.

Intervention Type PROCEDURE

Laparoscopic appendectomy

Laparoscopic appendectomy will be performed under general anesthesia by surgeons with experience in \> 20 procedures, according to standard clinical practice. The resected appendix will be examined for gross features and sent for histopathological confirmation of acute uncomplicated appendicitis. If laparoscopic appendectomy is unsuccessful, conversion to open appendectomy will be performed.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ERAT LA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years.
2. Diagnosis of first-episode acute uncomplicated appendicitis (AUA) confirmed by CT scan of the lower abdomen. AUA is defined as acute appendicitis without evidence of abscess, perforation, gangrene, or tumor.
3. Provision of written informed consent.

Exclusion Criteria

1. Complicated appendicitis, defined as acute appendicitis with perforation, gangrene, periappendiceal abscess or phlegmon, generalized peritonitis, or radiologic evidence of extraluminal appendicolith, extraluminal air, periappendiceal fat stranding, or appendiceal mass.
2. Severe intestinal adhesions or bowel obstruction.
3. Intolerance or contraindication to bowel preparation or colonoscopy (e.g., intestinal perforation or bowel obstruction).
4. Poor general condition precluding tolerance of abdominal surgery.
5. Abdominal pain caused by other diseases as confirmed by CT or other diagnostic examinations, including inflammatory bowel disease, urinary tract disease, or gynecological disease.
6. Pregnancy.
7. Severe dysfunction of major organ systems, including but not limited to cardiac, pulmonary, renal, hepatic, or hematologic systems.
8. Current enrollment in another clinical trial.
9. Any condition that may prevent the participant from completing all study requirements.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Micro-Tech (Nanjing) Co., Ltd.

INDUSTRY

Sponsor Role collaborator

Changhai Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhuan Liao

Zhuan Liao

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chingqing, China

Site Status

Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

Site Status

Department of Gastroenterology, South China Hospital, Medical School, Shenzhen University

Shenzhen, Guangdong, China

Site Status

Department of Gastroenterology, The First Affiliated Hospital of Henan University,

Kaifeng, Henan, China

Site Status

Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Site Status

Department of Gastrointestinal Surgery, Hunan Provincial People's Hospital

Changsha, Hunan, China

Site Status

Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University

Changsha, Hunan, China

Site Status

Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Site Status

Department of Gastroenterology, The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Site Status

Department of Gastroenterology, Jilin City People's Hospital

Jilin, Jilin, China

Site Status

Department of Gastroenterology, Linyi People's Hospital

Linyi, Shandong, China

Site Status

Department of Gastrointestinal Surgery, Fourth West China Hospital, Sichuan University

Chengdu, Sichuan, China

Site Status

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, , China

Site Status

Department of Gastroenterology, Changhai Hospital, Naval Medical University

Shanghai, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhuan Liao, MD, PhD

Role: CONTACT

021-81873001

Saif Ullah, MD, PhD

Role: CONTACT

008615538100231

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Song He, MD, PhD

Role: primary

13808336120

Zhen He, MD, PhD

Role: primary

Si-Lin Huang, MD, PhD

Role: primary

13512756686

Wen-Yi Yang, MD, PhD

Role: primary

008615890922163

Bing-Rong Liu, MD, PhD

Role: primary

008613313695959

Dan Liu, MD, PhD

Role: backup

0086183 3980 0019

Chao-Wu Chen, MD, PhD

Role: primary

008613298682898

Wei-Dong Liu, MD, PhD

Role: primary

008613873124855

Yong-You Wu, MD, PhD

Role: primary

008613338706607

Yin Zhu, MD, PhD

Role: primary

008613970841464

Hong-Guang Wang, MD, PhD

Role: primary

008618904421817

Liying Tao, MD, PhD

Role: backup

13689866436

Ling-Jian Kong, MD, PhD

Role: primary

0086157 1369 8818

Juan Liao, MD, PhD

Role: primary

00618780267956

Ji-Chao Qin, MD, PhD

Role: primary

008613628683363

Zhuan Liao, MD, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-APPEND

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.